Free Trial
NASDAQ:MNKD

MannKind (MNKD) Stock Price, News & Analysis

MannKind logo
$3.77 -0.03 (-0.79%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$3.78 +0.01 (+0.16%)
As of 07/11/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About MannKind Stock (NASDAQ:MNKD)

Key Stats

Today's Range
$3.73
$3.80
50-Day Range
$3.54
$4.96
52-Week Range
$3.51
$7.63
Volume
1.82 million shs
Average Volume
2.44 million shs
Market Capitalization
$1.15 billion
P/E Ratio
37.70
Dividend Yield
N/A
Price Target
$10.33
Consensus Rating
Buy

Company Overview

MannKind Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
49th Percentile Overall Score

MNKD MarketRank™: 

MannKind scored higher than 49% of companies evaluated by MarketBeat, and ranked 638th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    MannKind has received a consensus rating of Buy. The company's average rating score is 3.29, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    MannKind has received no research coverage in the past 90 days.

  • Read more about MannKind's stock forecast and price target.
  • Earnings Growth

    Earnings for MannKind are expected to grow by 130.00% in the coming year, from $0.10 to $0.23 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of MannKind is 37.70, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.84.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of MannKind is 37.70, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 28.13.

  • Read more about MannKind's valuation and earnings.
  • Percentage of Shares Shorted

    8.54% of the float of MannKind has been sold short.
  • Short Interest Ratio / Days to Cover

    MannKind has a short interest ratio ("days to cover") of 10.3, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in MannKind has recently increased by 3.80%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    MannKind does not currently pay a dividend.

  • Dividend Growth

    MannKind does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    8.54% of the float of MannKind has been sold short.
  • Short Interest Ratio / Days to Cover

    MannKind has a short interest ratio ("days to cover") of 10.3, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in MannKind has recently increased by 3.80%, indicating that investor sentiment is decreasing.
  • News Sentiment

    MannKind has a news sentiment score of 0.90. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for MannKind this week, compared to 5 articles on an average week.
  • Search Interest

    Only 5 people have searched for MNKD on MarketBeat in the last 30 days. This is a decrease of -44% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, MannKind insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $846,298.00 in company stock.

  • Percentage Held by Insiders

    Only 2.70% of the stock of MannKind is held by insiders.

  • Percentage Held by Institutions

    49.55% of the stock of MannKind is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about MannKind's insider trading history.
Receive MNKD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MannKind and its competitors with MarketBeat's FREE daily newsletter.

MNKD Stock News Headlines

This Cold War “Accident” Could Unleash New $100 Trillion AI Boom
Obscure Metal More Valuable than Gold and Bitcoin… COMBINED? This strange "AI Metal" holds the key to the $100 trillion AI boom. Which is why Jeff Brown recently traveled to a location that has one of the highest concentrations of this metal in the world. And you won't believe what he uncovered.
See More Headlines

MNKD Stock Analysis - Frequently Asked Questions

MannKind's stock was trading at $6.43 at the beginning of the year. Since then, MNKD stock has decreased by 41.4% and is now trading at $3.77.

MannKind Corporation (NASDAQ:MNKD) released its quarterly earnings data on Thursday, May, 8th. The biopharmaceutical company reported $0.04 EPS for the quarter, topping the consensus estimate of $0.03 by $0.01. The firm's quarterly revenue was up 18.1% on a year-over-year basis.
Read the conference call transcript
.

Top institutional investors of MannKind include Aaron Wealth Advisors LLC (0.07%), Towerpoint Wealth LLC (0.01%) and Farther Finance Advisors LLC. Insiders that own company stock include Michael Castagna, Stuart A Tross, Steven B Binder, David Thomson and Alejandro Galindo.
View institutional ownership trends
.

Shares of MNKD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that MannKind investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Bausch Health Cos (BHC), Intel (INTC) and Netflix (NFLX).

Company Calendar

Last Earnings
5/08/2025
Today
7/12/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:MNKD
CIK
899460
Employees
400
Year Founded
1991

Price Target and Rating

High Price Target
$12.00
Low Price Target
$8.00
Potential Upside/Downside
+174.1%
Consensus Rating
Buy
Rating Score (0-4)
3.29
Research Coverage
7 Analysts

Profitability

EPS (Trailing Twelve Months)
$0.10
Trailing P/E Ratio
37.70
Forward P/E Ratio
37.70
P/E Growth
N/A
Net Income
$27.59 million
Net Margins
10.12%
Pretax Margin
11.17%
Return on Equity
-32.41%
Return on Assets
10.85%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.36
Quick Ratio
2.11

Sales & Book Value

Annual Sales
$285.50 million
Price / Sales
4.01
Cash Flow
$0.14 per share
Price / Cash Flow
27.38
Book Value
($0.29) per share
Price / Book
-13.00

Miscellaneous

Outstanding Shares
303,930,000
Free Float
295,727,000
Market Cap
$1.15 billion
Optionable
Optionable
Beta
0.96

Social Links

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

This page (NASDAQ:MNKD) was last updated on 7/12/2025 by MarketBeat.com Staff
From Our Partners